Mr. Patrick Fabbio's most recent trade in BeyondSpring Inc was a trade of 22,165 Stock Options (right to buy) done . Disclosure was reported to the exchange on April 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BeyondSpring Inc | Mr. Patrick Fabbio | Director | 01 Apr 2026 | 22,165 | 22,165 | - | - | Stock Options (right to buy) | ||
| Protara Therapeutics Inc | Mr. Patrick Fabbio | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.67 per share. | 26 Jan 2026 | 3,261 | 64,115 (1%) | 0% | 6.7 | 21,751 | Common Stock |
| Protara Therapeutics Inc | Mr. Patrick Fabbio | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.60 per share. | 20 Jan 2026 | 3,063 | 67,376 (1%) | 0% | 5.6 | 17,153 | Common Stock |
| Protara Therapeutics Inc | Mr. Patrick Fabbio | Chief Financial Officer | 16 Jan 2026 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | ||
| Protara Therapeutics Inc | Mr. Patrick Fabbio | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2026 | 28,000 | 70,439 (1%) | 0% | 0 | Common Stock | |
| BeyondSpring Inc | Mr. Patrick Fabbio | Director | 21 Apr 2025 | 23,793 | 23,793 | - | - | Stock Options (right to buy) | ||
| Protara Therapeutics Inc | Mr. Patrick Fabbio | Chief Financial Officer | 24 Jan 2025 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | ||
| Protara Therapeutics Inc | Mr. Patrick Fabbio | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2025 | 23,500 | 45,500 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Mr. Patrick Fabbio | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.76 per share. | 21 Jan 2025 | 3,061 | 18,939 (0%) | 0% | 4.8 | 14,570 | Common Stock |
| Protara Therapeutics Inc | Mr. Patrick Fabbio | Chief Financial Officer | 19 Jan 2024 | 131,000 | 131,000 | - | - | Stock Option (Right to Buy) | ||
| Protara Therapeutics Inc | Mr. Patrick Fabbio | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2024 | 22,000 | 22,000 (0%) | 0% | 0 | Common Stock | |
| Protara Therapeutics Inc | Mr. Patrick Fabbio | Chief Financial Officer | 30 Jan 2023 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | ||
| Rafael Holdings Inc (Class B) | Mr. Patrick Fabbio | CFO & President | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.76 per share. | 21 Dec 2022 | 27,928 | 335,175 (2%) | 0% | 1.8 | 49,153 | Class B Common Stock, par value $.01 per share |
| Rafael Holdings Inc (Class B) | Mr. Patrick Fabbio | CFO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 363,103 | 363,103 (2%) | 2% | 0 | Class B Common Stock, par value $.01 per share |